2 Key Players In The GLP-1 Market Novo Nordisk Positioning: Novo Nordisk (Novo) is the undisputed leader in the GLP-1 receptor agonist market, largely due to the success of semaglutide, which is marketed as Ozempic for diabetes and Wegovy for weight management
GLP-1 is also made in neuronal populations in the brain and under certain circumstances by alpha cells [in the pancreas]
Its long-term effectiveness and safety remain inconclusive
evaluated the 2-week effect of liraglutide in a high-fat (60%), high-cholesterol (1.25%), and high-cholic acid (0.5%) along with hydroxypropyl--cyclodextrin (2%) in drinking water (HFCC-CDX) dietary mouse model of NASH and demonstrated that liraglutide decreased caloric intake and body weight and improved insulin resistance
Some GLP-1 users report strong food aversions, or strong aversions to specific foods, often driven by the smell or taste
In fact, THE APRILAB has nearly received approval from Badan Pengawas Obat dan Makanan (BPOM), also known as the Indonesian Food and Drug Authority, for distribution in the country